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Adventitial remodeling with increased matrix metalloprotein-
ase-2 activity in a porcine arteriovenous polytetrafluoroethy-
lene grafts.
Background. We hypothesized the source of early proliferat-
ing cells contributing to venous stenosis formation in a porcine
hemodialysis grafts is the adventitia and media, and migration of
these cells is greatest within the first two weeks following graft
placement, resulting in increased matrix metalloproteinase-2
(MMP-2) activity.
Methods. Polytetrafluoroethylene grafts from the iliac artery
to the ipsilateral iliac vein were placed in 23 pigs and 5-Bromo-
2′-deoxyuridine (BrdU) was given at 24 and 48 hours after
surgery to assess cell proliferation and migration. Angiography
and magnetic resonance angiography was performed. Animals
were euthanized on day three (N = 6), day seven, (N = 5), day
14 (N = 6), and days 19 to 26 (N = 6) after graft placement,
and stenotic tissue and unaffected contralateral iliac vein were
removed for zymography and immunostaining.
Results. Migration of cells derived from the adventitia and
media peaked at day 14. Adventitial diameter of the stenotic
vein decreased, while the intima to media ratio increased. MMP-
2 activity peaks at day seven in the adventitia and days 19 to 26
in the intima.
Conclusion. These results confirm our hypothesis that the
source of cells resulting in venous stenosis formation is de-
rived from the adventitia and media, with cell migration being
greatest within the first two weeks after graft placement with
translocation of these cells into the intima at four weeks. MMP-
2 activity peaks at day seven in the adventitia and again at days
19 to 26 in the intima. A key to limiting venous stenosis for-
mation may lie in inhibiting MMP-2 by adventitial and medial
targeting.
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There are currently more than 400,000 patients with
end-stage renal disease (ESRD) in the United States [1].
Because of the shortage of kidneys available for renal
transplantation, the vast majority of the patients require
hemodialysis as the major mode of renal replacement
therapy. Although arteriovenous fistulas are preferred
as vascular access for hemodialysis, expanded polyte-
trafluoroethylene (PTFE) arteriovenous (AV) grafts are
commonly used for dialysis access in many patients. A
major shortcoming of expanded polytetrafluoroethylene
(PTFE) AV grafts is the durability, with average graft pa-
tency being only 18 to 24 months [2, 3]. Data indicate
that most PTFE AV grafts fail because of the formation
of a stenosis at the vein-to-graft anastomosis or in the
proximal outflow vein. Moreover, stenoses have been hy-
pothesized to cause graft thrombosis [4]. In the first year
of hemodialysis, as many as 25% of all hospitalizations
and as much as 50% of all health care costs observed in
ESRD patients can be attributed to care related to vas-
cular access. Estimates suggest that these costs may be
more than one billion dollars [3, 4]. However, the specific
mechanisms initiating venous stenosis remain unknown.
Several theories have been proposed to explain the
pathogenesis of venous stenosis in patients with PTFE
AV grafts as the vascular access for hemodialysis. One
theory suggests that elastic mismatch between the PTFE
graft and vein contributes to thrombosis and vascular re-
modeling [5, 6]. This possibility is in addition to mechani-
cal forces that are attributable to increased shear stresses,
turbulent flow, and changes in flow velocities observed
in the grafts. Other theories suggest that the surface of
the graft may be a platform for increased platelet acti-
vation, resulting in the release of growth factors such as
platelet-derived growth factor (PDGF) after numerous
punctures for dialysis access [7, 8]. In addition, studies
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have also suggested that the intimal hyperplasia may stem
from increased cellular proliferation in the media accom-
panied by cell migration into the intima. This may be
followed by further proliferation and matrix deposition
resembling the arterial restenosis observed to occur af-
ter angioplasty [9–11]. In aggregate, current data in the
literature suggest that the pathogenesis underlying the
failure of PTFE hemodialysis grafts may be a multifac-
torial pathophysiologic process related to a combination
of thrombotic and stenotic events. However, the source
of the cells and both the time and kinetics of the cel-
lular involvement in venous stenosis formation remain
unknown. We hypothesized that the early source of prolif-
erating cells contributing to venous stenosis formation in
a porcine polytetrafluoroethylene (PTFE) arteriovenous
(AV) graft model is the adventitia and media, and second,
migration of these cells is greatest within the first two
weeks following graft placement. In the present paper,
we present a set of experiments designed to test our hy-
pothesis. Matrix metalloproteinase-2 is a protein that has
been implicated in stenosis formation in other vascular
injury models (e.g., arterial injury following angioplasty
or saphenous vein injury when these veins are used as
interposition arterial bypass grafts) [12–14]. Knowledge
of these data also prompted us to test the hypothesis that
increased matrix metalloproteinase 2 (MMP-2) activity
may occur at the venous stenosis site within the first two
weeks following graft placement. The knowledge gained
from this current study may help in designing and devel-
oping future therapies aimed at inhibiting the formation
of venous stenoses, thereby prolonging dialysis AV graft
patency in humans with ESRD.
METHODS
Because animals were used in the current studies, In-
stitutional Animal Care and Use Committee approval
was obtained prior to performing any procedures on ani-
mals. In addition, housing and handling of the animals was
performed in accordance with the Public Health Service
Policy on Humane Care and Use of Laboratory Animals
revised in 2000 [15].
Placement of polytetrafluoroethylene AV grafts
This was performed as initially described by Johnson
et al [16], except only one PTFE graft per animal was
placed while the contralateral vessels served as controls.
Briefly, PTFE grafts (4-mm diameter by 2-cm length;
Impra, Tempe, AZ, USA) were placed in 23 castrated
juvenile male pigs weighing from 30 to 40 kg from either
the right or left iliac artery to the ipsilateral iliac vein (see
Fig. 1A). Twelve hours prior to the placement of the graft,
an oral dose of aspirin (325 mg) was administered and
subsequently continued daily until the animals were eu-
thanized. The grafts were placed using a retroperitoneal
approach as described previously [16]. Briefly, the iliac
artery and vein were accessed and dissected from the sur-
rounding tissue. A bolus of heparin (100 U/kg) was given
intravenously, and the activated clotting time was moni-
tored hourly and maintained at 250 to 300 seconds. Fol-
lowing clamping of the iliac vein, a venotomy (0.5–1 cm)
was made, and an end-to-side PTFE graft-to-vein anasto-
mosis was created using 8–0 expanded PTFE sutures. Af-
ter arterial clamping, an arteriotomy (5–7 mm) was made,
and an end-to-side PTFE graft-to-artery anastomosis was
created using 8–0 expanded PTFE sutures. The fascia was
closed with a running 2–0 polypropylene suture, and the
skin was closed with a running 4–0 polyglactin subcutic-
ular suture. The contralateral iliac vein was isolated as
described previously to serve as control vessel. The fas-
cia on the control side was also closed with a running 2–0
Prolene suture, and the skin was closed with a running
4–0 Vicryl subcuticular suture.
Prior to euthanasia, angiography or magnetic res-
onance imaging/magnetic resonance angiography
(MRI/MRA) was used to quantify the amount of
stenosis, and also to determine the patency of the grafts
involving the experimental vessels and control vessels.
Methods for angiography and MRI/MRA are described
below.
Angiography
Before grafts were placed, angiography was performed
to assess baseline vessel size and to quantitate the amount
of venous stenosis after graft placement. Prior to graft
retrieval, angiography was also used to identify patent
grafts. Only patent grafts and proximal venous outflow
segments were removed. Briefly, through a longitudi-
nal incision, the right carotid artery was accessed and
a 6F sheath placed. A 5F, 2-cm marker catheter (Cook,
Bloomington, IN, USA) was advanced into the distal ab-
dominal aorta to obtain digital subtraction angiograms
in the frontal and both oblique projections prior to graft
placement and also prior to graft retrieval. The angiogram
was carried into the venous phase to determine the di-
ameter of the iliac vein before graft placement. Vessel
size was determined using Analyze 7.5 (Mayo Clinic and
Mayo Foundation, Rochester, MN, USA); for details, see
the section on angiographic measurements. After the an-
giograms were obtained, the sheath was removed and
the carotid arteriotomy was closed with 6–0 Prolene su-
ture. Angiograms were repeated prior to sacrificing the
animals. The fascia was closed with running 2–0 Vicryl su-
ture and the skin with 4–0 Vicryl subcuticular suture. The
intravenous ear vein catheter was sutured in place with
2–0 Prolene suture for the administration of 5-Bromo-2′-
deoxyuridine (see below). Each pig was extubated and
monitored postoperatively, and given 325 mg of aspirin
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Fig. 1. Representative angiograms of venous stenoses. (A) Placement of polytetrafluoroethylene hemodialysis graft. Internal iliac arteries are not
shown. CA, control iliac artery; CV, control iliac vein; IVC, inferior vena cava; PTFE, polytetrafluoroethylene; VA, venous anastomosis, GA, grafted
artery. Panels B and C are from the same animal. (B) Before graft implantation, angiogram showing arterial anatomy. (C) Mild stenosis (arrow)
distal to vein-to-graft anastomosis by day three. (D) Intragraft stenosis (arrow) by day seven. (E) High grade stenosis (arrow) by day 26.
by mouth daily until sacrifice. Angiographic studies were
performed in seven pigs.
Magnetic resonance imaging/magnetic resonance
angiography (MRI/MRA)
In 16 animals, magnetic resonance (MR) examina-
tion was performed the night prior to euthanasia. All
MR examinations used a Signa CVi 1.5Tesla system (GE
Medical Systems, Milwaukee, WI, USA) with a torso-
phased array coil positioned over the pelvis. After an
initial three-plane localizing scan, a test bolus of gadopen-
tetate dimeglumine (1–2 mL) was given (Magnevist;
Berlex Laboratories, Wayne, NJ, USA), followed by a
20-mL saline flush injected at 3 mL per second. A single
slice overlying the lower abdominal aorta was scanned
repeatedly about once per second and the time delay was
noted between the injection of the contrast medium and
its arrival in the lower aorta. In animals with patent grafts,
contrast medium was visualized in the inferior vena cava
(IVC) at the same time or within one second of visualiza-
tion in the aorta.
Gadolinium-enhanced three-dimensional (3-D) MRA
was performed in a coronal oblique plane that included
the lower aorta and iliac arteries. The scan parameters
were TR 5 ms, TE 1.7 ms, flip angle 35◦, 0.75 excitations,
0.75 phase field of views (FOVs), 62.5-kHz receiver band-
width, elliptic-centric phase-encoding, 256 × 192 scan
matrix, and 20 cm × 15 cm FOV, giving an in-plane resolu-
tion of 0.78 mm × 0.78 mm. Thirty to 40 sections (1.2 mm
to 1.4 mm) were obtained with 50% overlapping recon-
struction in the z-direction. The scan time was 20 seconds
to 25 seconds. Contrast medium (30-mL) was injected at
3 mL per second, followed by a 20-mL saline flush at the
same rate. An appropriate scan delay derived from the
test bolus sequence was chosen to ensure that the acqui-
sition of the central portion of k-space corresponded with
peak arterial enhancement.
The two-dimensional cine phase-contrast MRI se-
quences were conducted immediately after the 3-D
MRA. Acquisitions were positioned perpendicular to the
appropriate vessels at locations selected from maximum-
intensity projection images and reformatted images from
the 3-D MRA (Fig. 1A) as follows: (1) iliac vein 2 cm
cephalad to the venous anastomosis (VA) and (2) con-
tralateral control iliac vein (CV). Scan variables were
TR 13.2 ms, TE 4.9 ms, flip angle 30◦, 1 excitation, re-
ceiver bandwidth 15.6 kHz, 256 × 224 matrix, and 14-cm
FOV, for an in-plane resolution of 0.55 mm × 0.62 mm.
Slice thickness was 5 mm. The velocity-encoding gradi-
ent was set to 100 cm per second, unless aliasing was
identified on initial acquisitions. Electrocardiogram trig-
gering was provided by a peripheral pulse oximeter. Ac-
quisition times generally were 20 to 30 seconds. Imaging
planes (slices) were placed perpendicular to the vein, with
positioning guided by MRA images. Using retrospective
gating and view sharing, the images were reconstructed
to 20 evenly spaced time points in the cardiac cycle. Seg-
mented k-space acquisition produced eight views per seg-
ment. Quantitative flow information was obtained only
in the direction perpendicular to the slice. All flow cal-
culations were made on an Advantix Windows worksta-
tion (Cardiac and Flow Analysis Tools, AW Release 4.0;
GE Medical Systems). This was performed by a dedi-
cated radiologist who was fellowship trained in magnetic
resonance imaging (J.F.G.). Because turbulence was visu-
ally observed at the anastomosed vein, the flow measure-
ments were repeated twice within 5-mm of each other
at the venous anastomosis and the averaged values from
these two measurements were used.
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Validation of flow measurements using a phantom model
The accuracy of contrast-enhanced MRA and cine
phase-contrast MRI was determined using a flow phan-
tom constructed with 2-, 4-, and 5-mm-diameter plastic
tubing attached to a cardiac bypass pump to generate an
arterial flow waveform, as reported previously from this
institution [17]. Briefly, flow was measured with a cine
phase-contrast sequence using segmented k-space acqui-
sition at true flow rates of 145 mL/min, 315 mL/min, or
540 mL/min with 14-, 20-, 26-, or 32-cm FOVs. Three dif-
ferent observers conducted flow measurements using PC
MRA.
The average iliac vein diameter measured 10 mm. The
5-mm-diameter tubing with an FOV of 14 cm (9 pix-
els) had less than a 2% rate of error at flow rates of
315 mL/min or 540 mL/min. For an FOV of 20 cm (6 pix-
els), less than a 1.5% rate of error occurred at 315 mL/min,
and a 2% to 4% rate of error occurred at 540 mL/min.
The accuracy of the graft with a 4-mm diameter was the
same as that for the graft with a 5-mm diameter. For 2-
mm-diameter tubing at a flow of 145 mL/min, the rate of
error was 2% to 14% with a 14-cm FOV (4 pixels), or 2%
to 23% with a 20-cm FOV (3 pixels).
Postoperative care
Cefazolin (GlaxoSmithKline, Philadelphia, PA, USA)
was given at a dose of 25 mg/kg IV prior to graft place-
ment. As prophylaxis against infection, Cefa-Tabs (Fort
Dodge Laboratories, Fort Dodge, IA, USA) were given
orally at a dose of 15 mg/kg twice daily given for five days
after graft placement. 5-Bromo-2′-deoxyuridine (BrdU,
30 mg/kg; Sigma Chemical Co., St. Louis, MO, USA) IV
was given at 24 and 48 hours after surgery to assess cell
proliferation and migration. After grafts were placed, an-
imals were euthanized on day three (N = 6), day seven
(N = 5), day 14 (N = 6), and days 19 to 26 (N = 6).
Tissue harvesting
At the time of graft retrieval, the animals were medi-
cated and anesthesia was started as described above. Fol-
lowing angiography or MRI/MRA, a midline abdominal
approach was used to access experimental and control
vessels. Iliac vessels were dissected free of the surround-
ing soft tissue. A heparin bolus of 250 U/kg was given
intravenously. The iliac artery supplying the graft was
cannulated proximal to the graft and ligated beyond it.
The recipient vein was dissected free beyond the anasto-
mosis and ligated above and below. Drainage was allowed
through an incision in this vessel, while the graft was per-
fused at physiologic pressure (100 mm Hg) with lactated
Ringer’s solution until clear of blood. Similarly, this was
performed simultaneously on the contralateral side, and
these vessels were used as controls. For final euthana-
sia, the animals were exsanguinated through the carotid
arterial sheath. The artery-to-graft-to-vein anastomosis
(approximately 2 cm proximal and cephalad to the steno-
sis) was also removed (Fig. 1A). Venous anastomosis and
control vein tissues were divided into alternating 10-mm
sections and snap frozen in liquid nitrogen for zymogra-
phy. They were fixed in 10% formalin for 24 hours, placed
in 70% ethanol, and finally embedded in paraffin wax for
immunohistochemistry (see later).
Angiographic measurements
Digital angiographic images were acquired as de-
scribed previously, scanned using Adobe Photoshop 5.5
(Adobe, San Jose, CA, USA), and converted to JPEG
format. They were imported into Analyze 7.5, which is a
semiautomated program. With the marker catheter as a
known reference, the diameter of the vessels was deter-
mined for each tissue section. The quantitative edge de-
tection algorithm was applied to the digitized gray value
of a proposed line perpendicular to the center axis of the
lumen. The gray value distribution along the perpendic-
ular line was maximal outside the lumen and minimal
in the middle of the lumen. The edge of the lumen was
defined by the position of the pixel with a gray value
equal to the average of the maximum and minimum.
This full-width/half-maximum distance calculates the di-
ameter of the vessel. A radiopaque tape was placed on
the pig relative to a known anatomic landmark to en-
sure equal positions at different time points (pre-graft
placement and at graft retrieval) when making the vessel
diameter calculations. Percent stenosis by digital angiog-
raphy was calculated for tissue segments venous anasto-
mosis using the following equation: 1–(diameter at graft
retrieval/diameter at pre-graft placement) × 100. For
MRA, percent stenosis by was calculated for tissue seg-
ments venous anastomosis using the following equation:
1–(area at graft retrieval/area of control vein) × 100.
Immunohistochemistry
Single-label immunohistochemistry for BrdU, MMP-
2, and Verhoeff’s elastic (VE) stains were performed on
paraffin-embedded sections of the venous anastomosis
(VA) and control vein (CV), as shown in Fig. 1A, using
the Vectastain Elite ABC system (Vector Laboratories,
Burlingame, CA, USA). Sections were deparaffinized
and hydrated, and endogenous peroxidase activity was
quenched by incubating the sections in 0.3% hydro-
gen peroxide in methanol (1:1) for 10 minutes. After
the sections were washed in phosphate-buffered saline
(PBS), antigen was retrieved by steaming the slides in
1 mmol/L EDTA, pH 8.0 (Sigma Chemical Co.) for
30 minutes. Sections were incubated with 5% horse serum
for 20 minutes to block nonspecific antibody staining.
Excess serum was blotted off, and the sections were
incubated with a primary mouse monoclonal antibody
2894 Misra et al: Adventitial remodeling with increased MMP-2 activity
against BrdU (1:100, Bu20a; DAKO, Carpinteria, CA,
USA). Slides were washed in PBS and subsequently in-
cubated with biotinylated secondary antibody for 30 min-
utes (horse antimouse IgG, 1:2000; Vector Laboratories),
Vectastain elite ABC reagent for 30 minutes, and stained
with diaminobenzidine-tetrahydrochloride substrate kit
(DAB, Vector Laboratories) for 10 minutes. They were
subsequently counterstained with Gill’s hematoxylin. Af-
ter the slides were dehydrated in graded alcohols and
acetone, cover slips were placed.
In addition, primary mouse monoclonal antibody
against MMP-2 (1:30, Clone 42-5D11; Chemicon,
Temecula, CA, USA) was used to localize MMP-2 ac-
tivity. Verhoeff’s elastic (VE) staining was performed as
well.
Quantitative image analysis
This was performed by an observer blinded to the
experiments (J.H.). Sections immunostained for BrdU
and Verhoeff’s elastic (VE) stains were viewed with an
Axioplan 2 Microscope (Zeiss, Oberkochen, Germany)
equipped with a Neo-Fluor × 20/0.50 objective and digi-
tized to capture a minimum of 1030 × 1300 pixels using
a Axiocam camera (Zeiss). Images covering one entire
cross-section from each section of the venous anasto-
mosis or control vein were acquired and analyzed using
KS 400 Image Analysis software (Zeiss). BrdU-positive
(brown) and total nuclei (brown + blue) were high-
lighted, in turn, by selecting the appropriate RGB (red-
green-blue) color intensity range and then counted. The
color intensity was adjusted for each section to account
for decreasing intensity of positive staining over time.
The BrdU indices (positive cells/total cells × 100) were
calculated for the intimal, medial, and adventitial layers
of each section. This was repeated twice to ensure in-
traobserver variability was less than 10%. These sections
were then also viewed with an Axioplan 2 Microscope
(Zeiss) equipped with a Neo-Fluor × 20/0.50 objective
and digitized to capture at least 1030 × 1300 pixels us-
ing an Axiocam camera (Zeiss). For each animal with a
patent graft, the BrdU index for the venous anastomosis
was subtracted from the BrdU index of the control ves-
sel for each layer (adventitia, media, and intima) of the
vessel.
The thickness of the intima, media, and adventitia for
both the venous anastomosis and control veins was deter-
mined by manually tracing the different layers of the ves-
sel wall following immunostaining with Verhoeff’s elastic
stain. The intima was defined as the area above the inter-
nal elastic lamina, which was easily determined from the
media because of the disorganized structure of the inti-
mal cells. The measurements were repeated a minimum
of four times and the average measurement for each sec-
tion per animal was used.
SDS-PAGE zymography
Specimens stored at −70◦C were allowed to thaw,
minced with a razor blade, and crushed with a mortar
and pestle in a small amount of lysis buffer contain-
ing protease inhibitor cocktail (Sigma Chemical Co.).
Each solution was placed in a separate 2.0-mL tube
sonicated for 6 minutes to enhance cell lysis and then
centrifuged at 10,000 rpm for 6 minutes. Protein con-
centrations of the supernatant were measured with a
Bio-Rad (Hercules, CA, USA) protein assay kit. A
volume of solution containing 100-lg of protein was
diluted in the same volume of 1X NOVEX nonreduc-
ing sodium dodecyl sulfate (SDS) sample buffer and
loaded onto 10% polyacrylamide gels containing 0.1%
gelatin (Bio-Rad). After electrophoresis, the gels were
incubated twice for 30 minutes in ∼10 volumes of 2.7%
Triton X-100 renaturing buffer and once for 30 min-
utes in ∼10 volumes of development buffer [200 mmol/L
NaCl, 50 mmol/L N-2-hydroxyethylpiperazine-N′−2-
ethanesulfonic acid (HEPES), pH 7.5, 5 mmol/L CaCl2,
20 lmol/L ZnCl2]. Then, the gels were incubated at 37◦C
in fresh development buffer for 18 to 96 hours and stained
in 40% methanol, 10% acetic acid, and 0.5% Coomassie
blue R-250 for 30 minutes, followed by destaining in
the same solution without dye. All gels were calibrated
with known high-molecular-weight standards. One well
of each gel had conditioned media from the U87 as-
trocytoma cell line (American Type Culture Collection,
Manassas, VA, USA) diluted to a concentration deter-
mined to degrade 50% of the gelatin substrate. This cell
line is known to secrete pro MMP-2 and MMP-2 and
served as an internal positive control and also allow for
quantification of the proteolytic activity across several
gels. Bands were semiquantitated by reverse image scan-
ning densitometry (Photoshop 5.5; Adobe). An area of
the gel image that was devoid of signal was assigned
to be the background value. Then, each band was ana-
lyzed for the density above background. To ensure that
the quantitation was accurate, the area quantitated for
each band was equal. The results were calculated and ex-
pressed as relative densitometric units/unit area. Relative
active protein was calculated by dividing the densitomet-
ric value in the active band by the total densitometric
value of the active and proactive bands. The difference
in MMP-2 or pro MMP-2 activity from the venous anas-
tomosis was subtracted from the MMP-2 or pro MMP-2
activity of the control vein.
Statistical analysis
The percent stenosis (digital and MRA), BrdU index,
adventitial diameter, intima-to-media ratio, pro MMP-2,
and MMP-2 were pooled for all patent grafts at each time
point. All values are expressed as mean ± SEM. Stu-
dent t test and one-way analysis of variance (ANOVA)
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Fig. 2. MRA at the venous stenosis in a day
14 animal. Axial 2D MRA cross sections ob-
tained superior (A) to inferior (D) through
venous stenosis at D14. In (D), the diameter
of the vein has increased inferior to the steno-
sis. Ar is the artery, V is the vein, G is the graft,
and DV is the dilated vein.
with Newman-Keuls multiple comparison post tests was
used to analyze data and compare groups. A P value of
less than 0.05 was considered significant. SAS version 8.0
(SAS Institute, Inc., Cary, SC, USA) was used for all sta-
tistical analyses.
RESULTS
Graft thrombosis
There were a total of 16 patent grafts with seven graft
thromboses. Only vessels from patent grafts were ana-
lyzed. There were five patent grafts at day three, four at
day seven, four at day 14, and two at days 19 to 26. Two
thromboses may have resulted because the animals did
not receive aspirin prior to surgery. In four animals, graft
thrombosis occurred in the day 26 group.
Angiographic and magnetic resonance imaging/magnetic
resonance angiography (MRI/MRA) examination
Venous stenoses formed reproducibly at the vein-to-
PTFE graft anastomosis as shown (Fig. 1B to E). An-
giograms from day three, day seven, and days 19 to 26
animals are shown with venous stenosis formation at the
venous anastomosis as indicated by the arrow. We ob-
served evidence of mild stenosis distal to the vein-to-graft
anastomosis by day three (Fig. 1C). Intragraft stenosis
was present by day seven (Fig. 1D), and high-grade steno-
sis was noted by day 26 (Fig. 1E). In Figure 2, axial 2D
MRA from a day 14 animal shows evidence of high-grade
venous stenosis formation. The amount of stenosis by dig-
ital angiograph was calculated by the change in diameter
as shown in Table 1. Stenosis by day three was 16.1 ±
5.6%, had increased to 25.2 ± 0.2% by day seven, and
was 44.3% ± 13.7% by days 19 to 26. Stenoses on days 19
Table 1. Amount of average percent stenosis by angiography at
different time points
Pig Average percent stenosis % SEM N
Day 3 16.1 5.6 2
Day 7 25.2 0.2 2
Day 14 19.9 1
Days 19–26 44.3 13.7 2
Table 2. Amount of average percent stenosis by magnetic resonance
imaging at day three, seven, and 14
Pig Average percent stenosis % SEM N
Day 3 17.6 23.5 3
Day 7 32.6 8.1 2
Day 14 34 28.7 3
Table 3. Average blood flow measurements at day three, seven, and
14 (mL/min)
Location Day 3 Day 7 Day 14
Venous stenosis 1299.05 ± 62.09 1173.02 ± 95.09 820.50 ± 404.84
Control vein 739.71 ± 25.04 809.70 ± 38.95 645.58 ± 23.98
to 26 remained higher than day three for all subsequent
time points (P = NS). Similarly, the amount of stenosis
by MRI/MRA was measured by the change in area, as
shown in Table 2. By day three, the amount of stenosis
by MRI/MRA was 17.6 ± 23.5% and had increased to
32.6 ± 8.1% by day seven, and to 34 ± 28.7% (P = NS)
by day 14. Blood flow at the venous stenosis and control
vein was determined by MRI, as shown in Table 3. By
day three, the average blood flow at the venous steno-
sis was 1299.05 ± 62.09 mL/min, decreased to 1173.02 ±
95.09 by day seven, and was 820.50 ± 404.84 by day 14. In
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Fig. 3. H & E, BrdU, and MMP-2 immunostaining from the venous stenoses on days three, seven, 26, and control. (A–C) Day 3 (D3) slides from
the same animal. [(A and B), ×25, C (first panel), ×50, C (second panel)]. The arrow points to PTFE graft. L is the lumen of the vessel. Cells with
brown-staining nuclei are positive for BrdU. Cells with brown staining cytoplasm are positive for MMP-2. (D–F) Day 7 (D7) slides from the same
animal. [(D–F) (first panel), ×25, F (second panel). The arrow points to the intimal layer. A is the adventitia-to-media junction. (G–I) Day 26 (D26)
slides from the same animal. Arrow is pointing to the graft. L is the lumen. [(G–I) (first panel) ×50, I (second panel). (J–L) Control (contralateral
iliac vein) slides from the same animal. Arrow is pointing to the intima. (J, K, ×50; L, ×100).
contrast, the blood flow through the control vein re-
mained relatively the same.
Cell origin and migration
In order to determine the origin of the cells involved
in stenosis formation, BrdU immunostaining was per-
formed on venous stenotic tissue removed from patent
grafts. The brown staining nuclei are positive for BrdU
labeled cells. On day three (Fig. 3B), BrdU immunos-
taining is seen in all three layers. By day seven (Fig. 3E),
staining was observed at the adventitia-media junction,
and by day 26 (Fig. 3H), BrdU immunostaining was seen
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Fig. 4. Quantification of cell migration in
porcine PTFE AV grafts. Polytetrafluoroethy-
lene grafts were placed in castrated juve-
nile male pigs from either the right or left
iliac artery to the ipsilateral iliac vein. Im-
munohistochemistry for BrdU (migration of
proliferating cells labeled on days one and
two) by primary antibodies was performed on
paraffin-embedded sections from the venous
anastomosis. Sections were digitized and an-
alyzed using KS 400 Image Analysis software
(Zeiss). The BrdU proliferate indices (posi-
tive cells/total cells × 100) were calculated
separately in the intimal, medial, and adventi-
tial layers of each section and plotted as func-
tion of time. BrdU index at days 19 to 26 for
the intima is higher than the day three index.
primarily in the intima. Immunostaining of contralateral
iliac veins (normal vein) at similar time points demon-
strated minimal cell labeling with BrdU (Fig. 3K).
Quantitation of cell migration
As shown in Figure 4, the cell migration data were
quantified and expressed as the% of BrdU positive
cells/total cells per high power field in the adventitia, in-
tima, and media at the different time points. By day three,
cell migration in the adventitia at the venous anastomo-
sis was 17.4 ± 10.1 and remained the same by day seven.
However, by day 14, it had significantly decreased to 7.8 ±
3.3 and remained at 7.6 ± 0.05 by days 19 to 26. Interest-
ingly, in the media, cell migration was 10.1 ± 6.6 by day
three, peaked at 24.5 ± 12.3 by day seven, but decreased
to 12.3 ± 6.2 by day 14 and remained at 12.0 ± 8.7 by days
19 to 26. By day three, cell migration in the intima was
12.4 ± 10.9, increased to 15.7 ± 13.4 by day seven, 17.8 ±
9.0 by day 14, and subsequently to 25.6 ± 2.8 by day 26.
Collectively, these data support the hypothesis that the
cells derived from the adventitia and media migrate into
the intima. In addition, adventitial and medial cell mi-
gration is greatest in the first two weeks following graft
placement.
Adventitial diameter and intima to media ratio
In Figure 5A, we show that the mean adventitial di-
ameter of the venous anastomosis was 423.8 ± 101.9 lm
by day three, decreasing to 382.4 ± 79.8 by day seven,
and continuing to decrease to 225.8 ± 67.3 (day 14) and
finally to 81.1 ± 0 by days 19 to 26. Mean adventitial di-
ameter observed in control veins was 307.8 ± 103.5 at
day three, 339.8 ± 18.9 by day seven, and was 365.1 ±
67.3 by day 14, indicating the absence of any significant
change. As shown in Figure 5B, the mean intima-to-media
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Fig. 5. (A) Average adventitial thickness of the venous anastomosis
and control vein at different time points. (B) Average intima to media
ratio of the venous anastomosis at different time points.
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and MMP-2 activity as a function of time.
ratio of the venous anastomosis was 21.38 ± 11.62 by day
three and increased to 25.5 ± 8.7 by day seven. It peaked
at 29.7 ± 11.7 by day 14 but decreased to 17.3 ± 0 by
day 19.
Quantification of zymography
Matrix metalloproteinase-2 activity (both pro and ac-
tive) was quantified at the different time points from the
zymographic gels using densitometric quantification by
subtracting the MMP-2 activity in the venous stenosis
from the control vein (Fig. 6A). The mean pro MMP-2
activity varied. Results indicate that the mean pro MMP-
2 activity was 1.79 ± 4.24 by day three increased to 6.25 ±
3.9 by day seven, but decreased to 2.94 ± 1.24 by day 14
and significantly increased again to 10.0 ± 0 by days 19
to 26 (shown in Fig. 6B). Similar to the data observed for
the mean pro-MMP-2 activity, the mean active MMP-2
activity was 5.51 ± 2.74 by day three, increased to 6.95 ±
4.49 by day seven, transiently decreased to −4.74 ± 5.0
but increased to 13.3 ± 0 by days 19 to 26. These data indi-
cate a bimodal rise in MMP-2 activity that peaks initially
at day seven and then again from days 19 to 26 following
graft placement.
Localization of MMP-2
We used immunohistochemistry to localize the MMP-2
activity in the grafts and stenoses. The cytoplasm of cells
positive for MMP-2 stains brown. As shown in Figure 3C,
by day three, cells staining positive for MMP-2 were
found primarily in the adventitia. By day seven (Fig. 3F),
cells positive for MMP-2 were largely seen at the ad-
ventitia to media junction, and by day 26 (Fig. 3I), they
were primarily found in the intima. Interestingly, when
the MMP-2 activity and MMP-2 localization are com-
bined with the cellular migration data, they indicate that
increased MMP-2 activity may be necessary for cell mi-
gration to occur.
DISCUSSION
The experiments outlined in the present paper support
the hypothesis that the source of the early proliferating
cells causing venous stenosis formation is likely to be de-
rived from the adventitia and media. Moreover, adventi-
tial and medial cell migration is greatest in the first two
weeks after graft placement with translocation of these
cells into the intima by days 19 to 26 (N = 2). In addi-
tion, the MMP-2 activity at the venous stenosis peaks at
day seven after graft placement, followed by a later peak
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at day 26 (N = 2). The MMP-2 activity was localized by
immunohistochemistry at these time points and seems to
correlate with the cell migration.
Cell source and migration
The source of the cells and methods to evaluate cell
migration were determined by labeling dividing cells in
S phase with BrdU at day one and two after graft place-
ment. Immunostaining for BrdU in venous anastomotic
tissue removed from patent grafts at day three, day seven,
day 14, and days 19 to 26 (N = 2) after graft placement
was also used, as described previously [18–20]. By day
three to seven, immunostaining for BrdU positive cells
had peaked in the adventitia. By day 14 to days 19 to
26, adventitial BrdU immunostaining decreased as these
cells started to migrate to the media. By day three, medial
BrdU immunostaining had increased; by day seven it had
peaked and, subsequently, decreased by day 14 to days
19 to 26 as cells started to migrate from the adventitia to
the media. In the intima, BrdU immunostained positive
cells peaked at days 19 to 26 as cell migration continued
to occur from the media to the intima. The thickness of
the adventitia at the venous anastomosis decreased over
time when compared to the control vein and, finally, the
intima to media ratio increased over time. Patent grafts
were only used because it is difficult to determine intimal
hyperplasia in a thrombosed graft because thrombosis it-
self can cause intimal hyperplasia [21]. Taken collectively,
these data suggest that there is migration of cells from
the adventitia and media to the intima with depletion of
cells in the adventitia, as evidenced by the decrease in the
thickness of the adventitia.
These results are consistent with animal work per-
formed in other vascular injury models that investigated
the source of proliferating cells associated with vascular
wound healing [18–20]. When BrdU was administered af-
ter the placement of interposition saphenous vein grafts
in arteries, it was found that BrdU positive cells had mi-
grated from the adventitia to the intima over time [19,
20]. Similar results have been observed in vascular injury
caused by arterial dilatation, resulting in rupture of the
external elastic lamina [18]. In addition, decrease in ad-
ventitial thickness has been observed in coronary arterial
remodeling [21].
Matrix metalloproteinase-2 activity and localization
MMP-2 activity at the venous anastomosis was deter-
mined by zymography, which demonstrated a bimodal
peak in both the pro and active forms occurring at day
seven and days 19 to 26 (N = 2) after graft placement.
This activity was localized by immunohistochemistry to
the adventitia at days three to seven and at later time
points (day 26) to the intima. When the MMP-2 activity
and localization data are combined with the cell migra-
tion data, it suggests that increased MMP-2 activity may
be necessary for cell migration to occur. This is consistent
with different vascular injury models, such as balloon di-
latation of the artery [12, 13] and saphenous interposition
grafts placed in the arterial system, which demonstrated
increased MMP-2 activity following the vascular injury
[14]. A recent study showed that certain MMPs can cause
release of matrix bound VEGF-A [23], which could help
explain VEGF-A expression in venous stenoses observed
clinically [7]. These findings further confirm a recent pa-
per by Rotmans et al [24], which showed that the intima
to media ratio of the venous stenosis in pigs with arte-
riovenous PTFE grafts can be reduced by the use of a
MMP-2 inhibitor.
Angiographic and magnetic resonance imaging/magnetic
resonance angiography (MRI/MRA) examination
Angiography was performed which demonstrated pro-
gression of stenosis formation over time at the venous
anastomosis. This was further confirmed by MRI/MRA
and, as expected, showed an increase in stenosis forma-
tion at the venous anastomosis over time with a decrease
in the average blood flow at the venous anastomosis. The
amount of stenosis measured by angiography are consis-
tent with those described previously [16]. The different
imaging techniques used in this paper limit the observa-
tions that can be made; however, they provide estimates
for power analysis when planning preclinical therapeutic
studies.
Graft thrombosis
There were seven thromboses during the current study,
and this number could have been significantly reduced
by decreasing the length of follow-up because four of
the thromboses occurred at D19-D26. In addition, two
thromboses occurred in animals that did not receive an
aspirin prior to surgery. The thrombosis rate observed
in the present study is less than what has been reported
previously [16]; however, this may be because only one
graft per animal was placed in the present paper.
Limitations
A limitation of the present study is that not all the mi-
grating cells from different time points could have been
identified since BrdU was administered on day one and
two after graft and, therefore, only labeling cells dividing
in S phase at that time [25]; therefore, some of the BrdU
positive cells in the intima could have arisen from circu-
lating stem cells [22]. The observations made for days 19
to 26 group were derived from a small number of animals
(N = 2). Finally, the use of angiography and MRI/MRA in
animals significantly limits the observations which can be
drawn. The animals used were not uremic since clinically
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these grafts are placed in patients with kidney failure and
uremia.
CONCLUSION
The source of early proliferating cells causing venous
stenosis formation in arteriovenous polytetrafluoroethy-
lene grafts is in part from the adventitia and media and the
migration of these cells in the adventitia and media occurs
maximally in the first two weeks after graft placement. In
addition, there is adventitia and medial migration of cells
leading to venous stenosis formation with decrease in the
adventitial thickness and increase in the intima to media
ratio over time. Finally, there is bimodal peak in MMP-2
activity at day seven and day 26 after graft placement. The
key to limiting intimal hyperplasia causing venous steno-
sis formation in hemodialysis grafts may be in targeting
the adventitia or media with MMP-2 inhibitor within the
first two to four weeks after polytetrafluoroethylene graft
placement.
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